Thera-SAbDab

OTILIMAB

>   Structural Summary
TherapeuticOtilimab
TargetCSF2
Heavy ChainQVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMNWVRQAPGKGLEWVSGIENKYAGGATYYAASVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGFGTDFWGQGTLVTVSS
Light ChainDIELTQPPSVSVAPGQTARISCSGDSIGKKYAYWYQQKPGQAPVLVIYKKRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCSAWGDKGMVFGGGTKLTVL
100% seqID Fv StructureNone
99% seqID Fv Structure5c7x [Fvs: HL, MN], 5d7s [Fvs: HL]
95-98% seqID Fv Structure5d71 [Fvs: HL], 5d72 [Fvs: HL, MN]
>   Alignments

Non-identical sequences have been numbered using the Chothia scheme and aligned to Otilimab.
CDR positions are indicated in blue. Mismatching positions are highlighted in orange.

Sequence identity: 98.64%

Heavy chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 52A 52B 52C 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 82A 82B 82C 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 101 102 103 104 105 106 107 108 109 110 111 112 113
otilimab Q V Q L V E S G G G L V Q P G G S L R L S C A A S G F T F S S Y W M N W V R Q A P G K G L E W V S G I E N K Y A G G A T Y Y A A S V K G R F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y C A R G F G T D F W G Q G T L V T V S S
5c7x Q V Q L V E S G G G L V Q P G G S L R L S C A A S G F T F S S Y W M N W V R Q A P G K G L E W V S G I E N K Y A G G A T Y Y A A S V K G R F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y C A R G F G T D F W G Q G T L V T V S S

Light chain

Position 1 2 3 4 5 6 7 8 9 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107
otilimab D I E L T Q P P S V S V A P G Q T A R I S C S G D S I G K K Y A Y W Y Q Q K P G Q A P V L V I Y K K - R P S G I P E R F S G S N S G N T A T L T I S G T Q A E D E A D Y Y C S A W G D K G M V F G G G T K L T V L
5c7x - I E L T Q P P S V S V A P G Q T A R I S C S G D S I G K K Y A Y W Y Q Q K P G Q A P V L V I Y K K R - P S G I P E R F S G S N S G N T A T L T I S G T Q A E D E A D Y Y C S A W G D K G M V F G G G T K L T V L
Sequence identity: 98.64%

Heavy chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 52A 52B 52C 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 82A 82B 82C 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 101 102 103 104 105 106 107 108 109 110 111 112 113
otilimab Q V Q L V E S G G G L V Q P G G S L R L S C A A S G F T F S S Y W M N W V R Q A P G K G L E W V S G I E N K Y A G G A T Y Y A A S V K G R F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y C A R G F G T D F W G Q G T L V T V S S
5d7s Q V Q L V E S G G G L V Q P G G S L R L S C A A S G F T F S S Y W M N W V R Q A P G K G L E W V S G I E N K Y A G G A T Y Y A A S V K G R F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y C A R G F G T D F W G Q G T L V T V S S

Light chain

Position 1 2 3 4 5 6 7 8 9 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107
otilimab D I E L T Q P P S V S V A P G Q T A R I S C S G D S I G K K Y A Y W Y Q Q K P G Q A P V L V I Y K K - R P S G I P E R F S G S N S G N T A T L T I S G T Q A E D E A D Y Y C S A W G D K G M V F G G G T K L T V L
5d7s - I E L T Q P P S V S V A P G Q T A R I S C S G D S I G K K Y A Y W Y Q Q K P G Q A P V L V I Y K K R - P S G I P E R F S G S N S G N T A T L T I S G T Q A E D E A D Y Y C S A W G D K G M V F G G G T K L T V L
Sequence identity: 96.36%

Heavy chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 52A 52B 52C 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 82A 82B 82C 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 101 102 103 104 105 106 107 108 109 110 111 112 113
otilimab Q V Q L V E S G G G L V Q P G G S L R L S C A A S G F T F S S Y W M N W V R Q A P G K G L E W V S G I E N K Y A G G A T Y Y A A S V K G R F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y C A R G F G T D F W G Q G T L V T V S S
5d72 Q V Q L V E S G G G L V Q P G G S L R L S C A A S G F T F S S Y W M N W V R Q A P G K G L E W V S G I E N K Y A G G A T Y Y A A S V K G R F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y C A R G F G T D F W G Q G T L V T V S S

Light chain

Position 1 2 3 4 5 6 7 8 9 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107
otilimab D I E L T Q P P S V S V A P G Q T A R I S C S G D S I G K K Y A Y W Y Q Q K P G Q A P V L V I Y K K - R P S G I P E R F S G S N S G N T A T L T I S G T Q A E D E A D Y Y C S A W G D K G M V F G G G T K L T V L
5d72 - I E L T Q P P S V S V A P G Q T A R I S C S G D S I G K K Y A Y W Y Q Q K P G Q A P V L V I Y K K R - P S G I P E R F S G S N S G N T A T L T I S G T Q A E D E A D Y Y C S S W D S T G L V F G G G T K L T V L
Sequence identity: 94.97%

Heavy chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 52A 52B 52C 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 82A 82B 82C 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 101 102 103 104 105 106 107 108 109 110 111 112 113
otilimab Q V Q L V E S G G G L V Q P G G S L R L S C A A S G F T F S S Y W M N W V R Q A P G K G L E W V S G I E N K Y A G G A T Y Y A A S V K G R F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y C A R G F G T D F W G Q G T L V T V S S
5d71 Q V Q L V E S G G G L V Q P G G S L R L S C A A S G F T F S S Y W M N W V R Q A P G K G L E W V S G I S Y - - S G S E T Y Y A D S V K G R F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y C A R G F G T D F W G Q G T L V T V S S

Light chain

Position 1 2 3 4 5 6 7 8 9 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107
otilimab D I E L T Q P P S V S V A P G Q T A R I S C S G D S I G K K Y A Y W Y Q Q K P G Q A P V L V I Y K K - R P S G I P E R F S G S N S G N T A T L T I S G T Q A E D E A D Y Y C S A W G D K G M V F G G G T K L T V L
5d71 - I E L T Q P P S V S V A P G Q T A R I S C S G D S I G K K Y A Y W Y Q Q K P G Q A P V L V I Y K K R - P S G I P E R F S G S N S G N T A T L T I S G T Q A E D E A D Y Y C S A W G D K G M V F G G G T K L T V L
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (June '19)Phase-III
Estimated Status (June '19)Active
Recorded Developmental TechnologyMorphoSys HuCAL Phage Display
INN Year Proposed2018
INN Year Recommended2019
Companies InvolvedGlaxoSmithKline, MorphoSys
Conditions Approvedna
Conditions ActiveRheumatoid arthritis
Conditions DiscontinuedInflammation, Multiple sclerosis, Osteoarthritis
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]